NasdaqCM - Nasdaq Real Time Price USD

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

33.50 -2.04 (-5.74%)
At close: April 25 at 4:00 PM EDT
32.30 -1.20 (-3.58%)
After hours: April 25 at 5:11 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
881.71
3,937.23
Operating Expense
45,077.30
45,077.30
34,835.45
56,870.73
126,747.46
Operating Income
-45,077.30
-45,077.30
-34,835.45
-55,989.02
-122,810.23
Net Non Operating Interest Income Expense
-2,923.97
-2,923.97
-2,132.09
-1,830.49
-1,028.36
Other Income Expense
3,397.96
3,397.96
-5,379.37
12,179.08
12,569.21
Pretax Income
-44,603.32
-44,603.32
-42,346.90
-45,640.43
-111,269.38
Net Income Common Stockholders
-44,603.32
-44,603.32
-42,346.90
-45,640.43
-111,269.38
Diluted NI Available to Com Stockholders
-44,603.32
-44,603.32
-42,346.90
-45,640.43
-111,269.38
Basic EPS
-11.12
-10.31
-10.15
-11.10
-42.60
Diluted EPS
-11.12
-10.31
-10.15
-11.10
-42.60
Basic Average Shares
4,264.21
4,327.57
4,170.68
4,099.67
2,604.44
Diluted Average Shares
4,264.21
4,327.57
4,170.68
4,099.67
2,604.44
Total Operating Income as Reported
-45,077.30
-45,077.30
-39,835.45
-55,989.02
-122,810.23
Total Expenses
45,077.30
45,077.30
34,835.45
56,870.73
126,747.46
Net Income from Continuing & Discontinued Operation
-44,603.32
-44,603.32
-42,346.90
-45,640.43
-111,269.38
Normalized Income
-44,611.84
-44,611.84
-37,016.31
-45,919.52
-110,568.38
Net Interest Income
-2,923.97
-2,923.97
-2,132.09
-1,830.49
-1,028.36
EBIT
-45,077.30
-45,077.30
-34,835.45
-55,989.02
-122,810.23
EBITDA
-44,436.70
-44,436.70
-34,072.45
-54,349.79
-121,115.92
Reconciled Depreciation
640.60
640.60
763.00
1,639.23
1,694.31
Net Income from Continuing Operation Net Minority Interest
-44,603.32
-44,603.32
-42,346.90
-45,640.43
-111,269.38
Total Unusual Items Excluding Goodwill
8.52
8.52
-5,330.59
279.09
-701.00
Total Unusual Items
8.52
8.52
-5,330.59
279.09
-701.00
Normalized EBITDA
-44,445.22
-44,445.22
-28,741.86
-54,628.88
-120,414.92
12/31/2020 - 10/27/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

JANX Janux Therapeutics, Inc.
47.10
-2.30%
 
ELEV Elevation Oncology, Inc.
3.6450
-6.06%
 
APM Aptorum Group Limited
5.48
-1.44%
 
CYTK Cytokinetics, Incorporated
64.80
-3.02%
 
CADL Candel Therapeutics, Inc.
6.43
+6.28%
 
CGEM Cullinan Therapeutics, Inc.
19.25
+1.91%
 
LPTX Leap Therapeutics, Inc.
3.1700
-3.65%
 
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
 
PRAX Praxis Precision Medicines, Inc.
52.88
+3.40%
 
GYRE Gyre Therapeutics, Inc.
16.33
+1.74%